TABLE 1.

Sensitivity Analysis: SARS‐CoV‐2 Antibody Levels and Correlation with Percentage of Peripheral B cells After Excluding Patients with Ocrelizumab Treatment or mRNA‐1,273 (Moderna) Vaccine or Both

	SARS‐CoV‐2 S IgG levels (median BAU/ml, IQR)			Correlation between percentage of peripheral B cells and SARS‐CoV‐2 IgG S levels
	<1 B cell/μl	≥1 B cell/μl	p	Kendall rank correlation coefficient (τ)	p
Without ocrelizumab (n = 76)	0.2 (3.84)	1,101 (2286)	<0.001	0.66	<0.001
Without mRNA‐1,273 vaccine (n = 71)	0.44 (6.70)	1237.50 (2286)	<0.001	0.64	<0.001
Without ocrelizumab and mRNA‐1,273 vaccine (n = 65)	0.2 (6.06)	1237.50 (2286)	<0.001	0.65	<0.001

IQR = interquartile range; S = viral spike; SARS‐CoV‐2 = severe acute respiratory syndrome‐coronavirus 2.